{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:13:04Z","timestamp":1770682384338,"version":"3.49.0"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>After completion of a 6\u2010week double\u2010blind trial of asenapine sublingual tablets (10 or 20\u2009mg\/day) versus placebo in Asian patients with acute exacerbation of schizophrenia, including Japanese patients, this open\u2010label study evaluated the safety and efficacy of a 52\u2010week treatment with asenapine at flexible doses. In 201 subjects, including 44 who had received placebo (P\/A group) and 157 who had received asenapine (A\/A group) in the feeder trial, adverse events occurred at rates of 90.9% and 85.4% and serious adverse events at rates of 11.4% and 20.4%, respectively. One patient in the P\/A group died. No clinically significant abnormal measurements of body weight, body mass index, or glycated hemoglobin, fasting plasma glucose, insulin, and prolactin levels were observed. The sustained efficacy rate, as evaluated by the Positive and Negative Syndrome Scale total score and other measures, remained at approximately 50% between 6 and 12\u2009months of treatment. These results suggest that long\u2010term treatment with asenapine is well tolerated and provides sustained efficacy.<\/jats:p>","DOI":"10.1002\/npr2.12342","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T05:39:18Z","timestamp":1685079558000},"page":"328-337","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long\u2010term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase <scp>III<\/scp> extension study with follow\u2010up for 52\u2009weeks (<scp>P06125<\/scp>)\u2014Secondary publication"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9901-9753","authenticated-orcid":false,"given":"Toshihiko","family":"Kinoshita","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry Kansai Medical University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiteru","family":"Takekita","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Kansai Medical University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Tamura","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Iwama","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200507000-00001"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.03.005"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.11.82"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/11634500-000000000-00000"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10m06306"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.05.025"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082944"},{"issue":"6","key":"e_1_2_12_10_1","first-page":"803","article-title":"Asenapine review, part II: clinical efficacy, safety and tolerability","volume":"13","author":"Citrome L","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d35d6b"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1004"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4295-9"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1205"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100031\u20101295450"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1248313"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0115-5"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871530315666150623092031"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800721"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(02)00127-X"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/639391"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009344855"},{"issue":"4","key":"e_1_2_12_24_1","first-page":"4","article-title":"Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia","volume":"68","author":"Hennekens CH","year":"2007","journal-title":"J Clin Psychiatry"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T15:56:54Z","timestamp":1726070214000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.12342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/npr2.12342"],"URL":"https:\/\/doi.org\/10.1002\/npr2.12342","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"2022-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}